Skip to Main Content

Paper Details

Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial.
0
2023
Dexamethasone, Elotuzumab, Multiple Myeloma, Pomalidomide, dexamethasone, elotuzumab, multiple myeloma, patients, pomalidomide
Author NameAffiliation
Alexander Keith StewartUniversity Health Network, Princess Margaret Cancer Centre
Ravi VijWashington University School of Medicine
  • 1 - 2

Datasets

Release 1.2